Shenwan Hongyuan Group (06806): "26th batch of D9 securities" and "26th batch of D10 securities" will be listed on the Shenzhen Stock Exchange starting from July 2nd.
Shenwan Hongyuan Securities Co., Ltd., a subsidiary of Shenzhen Shenwan Hongyuan (HKG: 06806), announced the public issuance of short-term corporate bonds (fifth series) targeted at professional investors in 2026, with the issuance process ending on June 25, 2026. The total issuance size of this series of bonds is 6 billion RMB, with 1.4 billion RMB in the first category with a term of 175 days and a face value interest rate of 1.52%, and 4.6 billion RMB in the second category with a term of 365 days and a face value interest rate of 1.55%.
Shenwan Hongyuan Group (06806) announced that its subsidiary, Shenwan Hongyuan Group Securities Co., Ltd., will issue short-term corporate bonds for professional investors in 2026 (fifth series), referred to as "this bond". The issuance process of this bond ended on June 25, 2026. The total issuance size of this bond is 6 billion yuan, with 1 series issued at 1.4 billion yuan and a term of 175 days with a coupon rate of 1.52%, and the other series issued at 4.6 billion yuan with a term of 365 days and a coupon rate of 1.55%.
After review by the Shenzhen Stock Exchange, this bond will be listed on the Shenzhen Stock Exchange starting from July 2, 2026, for institutional investors among professional investors. The first series of bonds will be abbreviated as "26 SHHZ D9" with the bond code "524870", and the second series of bonds will be abbreviated as "26 SH D10" with the bond code "524871".
Related Articles
JIUYUAN GENE (02566) spent 299,600 Hong Kong dollars on July 2 to repurchase 50,000 shares.
The drug application for the injection of Rituximab monoclonal antibody by Jiangsu Hengrui Pharmaceuticals (01276) has been accepted and included in the priority review program.
As of June, COUNTRY GARDEN(02007)'s contract sales amounted to approximately RMB 24.5 billion.
JIUYUAN GENE (02566) spent 299,600 Hong Kong dollars on July 2 to repurchase 50,000 shares.
The drug application for the injection of Rituximab monoclonal antibody by Jiangsu Hengrui Pharmaceuticals (01276) has been accepted and included in the priority review program.
As of June, COUNTRY GARDEN(02007)'s contract sales amounted to approximately RMB 24.5 billion.
RECOMMEND
